1694-46-8Relevant academic research and scientific papers
ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION
-
Page/Page column 51-52, (2020/02/06)
The present invention relates to a compound of formula (I) wherein X1 represents an alkenylene group, a -NH-CO- group, a -CO-NH- group, Y1 represents an aryl group selected from a pyridyl group, a pyrazinyl group or a pyrimidinyl group, X2 represents a -O- group, a-CO-NH- group, a -NH-CO-NH- group, a -OCH2- group, a -NH-CO- group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms or a -SO2-NH- group, and Y2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or a -CR1R2R3 group or alternatively X2-Y2 represents a group -CONRcRd, wherein Rc and Rd form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification. The present invention further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.
Heterocyclic ethenyloxanilates as orally active antiallergic agents
Grozinger,Sorcek,Oliver
, p. 487 - 491 (2007/10/02)
Ethyl p-(pyrimidin-4-ylethenyl)oxanilate 2 and many substituted derivatives were found to have oral activity in the PCA assay. The pyrimidine moiety was replaced by other heterocycles but only pyrazine and pyridazine retained activity.
